GSE197555 trametinib A-549 NCI-H460 1 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE197555_trametinib_A-549 NCI-H460_1_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE197555_trametinib_A-549 NCI-H460_1_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE197555_trametinib_A-549 NCI-H460_1_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE197555_trametinib_A-549 NCI-H460_1_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

growth arrest specific 5

Gene

small nucleolar RNA host gene 29

Gene

small nucleolar RNA host gene 3

Gene

PAX8 antisense RNA 1

Gene

RNA polymerase II subunit J3

Gene

long intergenic non-protein coding RNA 2693

Gene

small nucleolar RNA host gene 7

Gene

NmrA like redox sensor 2, pseudogene

Gene

TMEM161B divergent transcript

Gene

ELFN1 antisense RNA 1

  • Gene

    growth arrest specific 5


  • Gene

    small nucleolar RNA host gene 29


  • Gene

    small nucleolar RNA host gene 3


  • Gene

    PAX8 antisense RNA 1


  • Gene

    RNA polymerase II subunit J3


  • Gene

    long intergenic non-protein coding RNA 2693


  • Gene

    small nucleolar RNA host gene 7


  • Gene

    NmrA like redox sensor 2, pseudogene


  • Gene

    TMEM161B divergent transcript


  • Gene

    ELFN1 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.